Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due June 12, 2026. Soligenix, in collaboration with Axel Lehrer, PhD, Professor in the Department of Tropical Medicine, Medical Microbiology and Pharmacology at the John A. Burns School of Medicine, University of Hawaiʻi at Mānoa, has previously developed bivalent and trivalent thermostable vaccines, constructed from antigens against Ebola virus, Sudan virus and Marburg virus and the CoVaccine HT™ adjuvant, demonstrating thermostability, immunogenicity and durable efficacy in non-human primates. This work, combined with previous and ongoing work in Dr. Lehrer's laboratory that has demonstrated platform compatibility of the key Bundibugyo virus antigen, will form the basis of an application to CEPI enabling rapid development of a protein-based thermostable subunit vaccine for BDBV.